JP5513126B2 - 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 - Google Patents

肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 Download PDF

Info

Publication number
JP5513126B2
JP5513126B2 JP2009541912A JP2009541912A JP5513126B2 JP 5513126 B2 JP5513126 B2 JP 5513126B2 JP 2009541912 A JP2009541912 A JP 2009541912A JP 2009541912 A JP2009541912 A JP 2009541912A JP 5513126 B2 JP5513126 B2 JP 5513126B2
Authority
JP
Japan
Prior art keywords
xanthohumol
isoxanthohumol
active substance
liver
weight
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2009541912A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010513360A (ja
JP2010513360A5 (OSRAM
Inventor
ヘレルブランド、クラウス
Original Assignee
フラキサン ゲーエムベーハー ウント コー. カーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by フラキサン ゲーエムベーハー ウント コー. カーゲー filed Critical フラキサン ゲーエムベーハー ウント コー. カーゲー
Publication of JP2010513360A publication Critical patent/JP2010513360A/ja
Publication of JP2010513360A5 publication Critical patent/JP2010513360A5/ja
Application granted granted Critical
Publication of JP5513126B2 publication Critical patent/JP5513126B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/121Ketones acyclic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/12Ketones
    • A61K31/122Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/348Cannabaceae
    • A61K36/3486Humulus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Obesity (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Mycology (AREA)
  • Botany (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
JP2009541912A 2006-12-22 2007-12-21 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用 Expired - Fee Related JP5513126B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006062264A DE102006062264A1 (de) 2006-12-22 2006-12-22 Verwendung von Xanthohumol zur Vorbeugung und/oder Bekämpfung von Lebererkrankungen
DE102006062264.2 2006-12-22
PCT/EP2007/011358 WO2008077618A1 (de) 2006-12-22 2007-12-21 Verwendung von xanthohumol bzw. isoxanthohumol als wirkstoff zur vorbeugung und/oder bekämpfung von lebererkrankungen

Publications (3)

Publication Number Publication Date
JP2010513360A JP2010513360A (ja) 2010-04-30
JP2010513360A5 JP2010513360A5 (OSRAM) 2011-01-13
JP5513126B2 true JP5513126B2 (ja) 2014-06-04

Family

ID=39186950

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009541912A Expired - Fee Related JP5513126B2 (ja) 2006-12-22 2007-12-21 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用

Country Status (7)

Country Link
US (1) US20100029757A1 (OSRAM)
EP (1) EP2120906B1 (OSRAM)
JP (1) JP5513126B2 (OSRAM)
CA (1) CA2672155C (OSRAM)
DE (1) DE102006062264A1 (OSRAM)
RU (1) RU2454996C2 (OSRAM)
WO (1) WO2008077618A1 (OSRAM)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10722575B2 (en) 2009-11-26 2020-07-28 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US8772342B2 (en) * 2009-11-26 2014-07-08 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
US9221751B2 (en) 2009-11-26 2015-12-29 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
EP2861202B1 (en) 2012-06-18 2018-07-18 3M Innovative Properties Company Powder composition for air polishing the surface of hard dental tissue
BR112015001595A2 (pt) * 2012-07-26 2018-06-19 Ta-Xan Ag composição farmacêutica, uso de um extrato torrado, e, método para intensificar um ou mais efeito (s) terapêutico (s) de xantohumol e para a produção de uma composição farmacêutica
WO2014099490A2 (en) 2012-12-17 2014-06-26 3M Innovative Properties Company Device for dispensing a dental material with locking mechanism
EP2742898A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Powder jet device for dispensing a dental material
EP2742897A1 (en) 2012-12-17 2014-06-18 3M Innovative Properties Company Nozzle head, hand piece and powder jet device for applying a dental material
US20180193287A1 (en) 2015-07-02 2018-07-12 John I. Haas, Inc. Hops-based substance and use of the substance
KR20190099481A (ko) * 2016-12-20 2019-08-27 산토리 홀딩스 가부시키가이샤 이소잔토휴몰을 함유하는 지질 대사 촉진용 조성물
DK3651804T5 (da) 2017-07-11 2023-10-09 Aquanova Ag Solubilisat med curcumin, boswellia og xanthohumol
RS64651B1 (sr) 2018-07-11 2023-10-31 Aquanova Ag Solubilizat ksantohumola
EP3820527B1 (de) * 2018-07-11 2023-08-23 Aquanova AG Xanthohumol-solubilisat
JP7348187B2 (ja) * 2018-08-10 2023-09-20 サントリーホールディングス株式会社 腸内環境改善用組成物及び腸内細菌叢改善方法
CN112584709A (zh) * 2018-08-10 2021-03-30 三得利控股株式会社 微生物增殖抑制剂、微生物污染防止方法及饮料
CN112566516A (zh) * 2018-08-10 2021-03-26 三得利控股株式会社 血糖值上升抑制用组合物及血糖值上升抑制方法
EP3834627A4 (en) * 2018-08-10 2022-05-04 Suntory Holdings Limited COMPOSITION FOR PROMOTING URIC ACID EXCRETION, COMPOSITION FOR INHIBITING URAT1 AND COMPOSITION FOR LOWERING URIC ACID LEVELS IN THE BLOOD
EP4291307A4 (en) * 2021-02-09 2025-01-22 Oregon State University Xanthohumol derivatives and methods for making and using
US20250009709A1 (en) * 2021-07-09 2025-01-09 INNOX Corp. Prenylated chalcone and flavonoid compositions for use in treating cancer

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07285856A (ja) * 1994-04-21 1995-10-31 Hoechst Japan Ltd 骨粗鬆症治療剤
DK0938304T3 (da) * 1996-08-30 2005-03-14 Nps Pharma Inc Isovaleramid til behandlingen af kramper, epilepsi, hovedpine og spasticitet
AU6174900A (en) 1999-07-08 2001-01-30 Patrick T. Prendergast Use of flavones, coumarins and related compounds to treat infections
JP3293601B2 (ja) * 1999-09-03 2002-06-17 松下電器産業株式会社 管球およびその製造方法
CN100457124C (zh) * 2000-04-10 2009-02-04 宝生物工程株式会社 治疗剂
US20040156950A1 (en) * 2001-04-05 2004-08-12 Green Martin Richard Use of hop components in foods
US20040219238A1 (en) * 2001-07-13 2004-11-04 Eiji Nishiyama Remedies
DE10308864B4 (de) 2003-02-28 2007-03-01 Paulaner Brauerei Gmbh & Co. Kg Neues Brauverfahren, damit gebrautes Bier und dessen Verwendung
EP1543834A1 (en) 2003-12-16 2005-06-22 Biodynamics Production of hop extracts having oestrogenic and antiproliferative bioactivity
CA2606329A1 (en) 2005-03-09 2006-09-21 Cardax Pharmaceuticals, Inc. Carotenoids, carotenoid analogs, or carotenoid derivatives for the treatment of proliferative disorders
JP2006306800A (ja) * 2005-04-28 2006-11-09 Kirin Brewery Co Ltd ファルネソイドx受容体活性化剤
KR20080063748A (ko) * 2005-07-29 2008-07-07 바이오액티브스, 인코포레이티드 프레닐플라보노이드 제형
MX2008001903A (es) * 2005-08-09 2008-04-16 Metaproteomics Llc Modulacion de proteina cinasa por medio de lupulos y productos de acacia.
JP5246834B2 (ja) * 2005-12-27 2013-07-24 独立行政法人産業技術総合研究所 アディポネクチン産生強化剤

Also Published As

Publication number Publication date
CA2672155C (en) 2013-10-01
JP2010513360A (ja) 2010-04-30
EP2120906B1 (de) 2015-04-22
DE102006062264A1 (de) 2008-06-26
RU2454996C2 (ru) 2012-07-10
US20100029757A1 (en) 2010-02-04
RU2009128213A (ru) 2011-01-27
CA2672155A1 (en) 2008-07-03
WO2008077618A1 (de) 2008-07-03
EP2120906A1 (de) 2009-11-25

Similar Documents

Publication Publication Date Title
JP5513126B2 (ja) 肝疾患を予防および/または制御するための、キサントフモールまたはイソキサントフモールの活性物質としての使用
AU780161B2 (en) Prophylactic and therapeutic use of oltipraz as an antifibrotic and anticirrhotic agent in the liver and pharmaceutical composition containing oltipraz
EP3391893A1 (en) Medicine composition for treating leukemia and preparation method therefor
JP6101803B2 (ja) 脳梗塞の予防及び治療のための薬の調製上の3−n−ブチルイソインドリノンの応用
JP2004091473A (ja) 色素沈着改善治療薬
JP2022019937A (ja) ヒト又は動物の慢性若しくは急性のウイルス感染症及び/又は敗血症の予防若しくは治療のための組成物
CN104758304B (zh) 三七皂苷r1的医药用途
KR20220161413A (ko) 코로나바이러스 감염의 억제 및 치료에 사용하기 위한 시알산 조성물
CN105078944A (zh) Isopaucifloral F在制备抗骨质疏松药物中的用途
EP1263435B1 (en) Pharmaceutical composition for treatment and prevention of liver fibrosis and cirrhosis
US20140066519A1 (en) Use of xanthohumol and/or isoxanthohumol as an agent for preventing and/or combating liver diseases
JP2018519342A (ja) ホップに基づく物質およびその物質の使用
CN102076346B (zh) 一种人用药物组合物及铋或锌剂的制备
JP6184960B2 (ja) メラトニンの新規用途
CN104758305A (zh) 三七皂苷Ft1的医药用途
CN106822152B (zh) 一种药物组合物及其应用
CN104587047B (zh) 一种用于治疗心脑血管疾病的中药组合物
KR102838311B1 (ko) Rls 치료를 위한 님
CN101579389A (zh) 一种治疗骨质疏松症的药物组合物
CN107648249A (zh) 去半乳糖替告皂甙在制备防治流感病毒感染的药物中的应用
JP2004115420A (ja) 気管支及び肺疾患の治療剤及びそれを含有する飲食品
CN120549927A (zh) 异喹啉生物碱ys-49在制备治疗流行性乙型脑炎病毒感染药物中的应用
CN105833051A (zh) 一种护心通络的药物组合物及含其制剂与应用
CN115040545A (zh) 鸡胆粉在制备解酒护肝药物中的用途
JP2005035918A (ja) いびき防止剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20101117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20101117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121011

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20121212

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20121219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130411

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20130808

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130812

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20131126

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140205

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20140218

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20140313

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140327

R150 Certificate of patent or registration of utility model

Ref document number: 5513126

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

LAPS Cancellation because of no payment of annual fees